Kyprolis and Fall - a phase IV clinical study of FDA data

Summary:

Fall is reported as a side effect among people who take Kyprolis (carfilzomib), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Pomalyst, and have Nausea and vomiting.

The phase IV clinical study analyzes which people have Fall when taking Kyprolis. It is created by eHealthMe based on reports of 15,068 people who have side effects when taking Kyprolis from the FDA, and is updated regularly.

What is Kyprolis?

Kyprolis has active ingredients of carfilzomib. It is often used in multiple myeloma. eHealthMe is studying from 15,080 Kyprolis users. Check the latest studies of Kyprolis.

What is Fall?

Fall is found to be associated with 3,288 drugs and 3,757 conditions by eHealthMe. Check the latest studies of Fall.

On Feb, 27, 2026

15,068 people reported to have side effects when taking Kyprolis.
Among them, 165 people (1.1%) have Fall.

Among these 165 people:

* Approximation only. Some reports may have incomplete information.

Do you take Kyprolis and have Fall?

- Check whether Fall is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kyprolis:

Kyprolis (15,080 reports)

Fall treatments and more:

Fall (403,513 reports)

How severe was Fall and when was it recovered:

Fall in Kyprolis

Expand to all the drugs that have ingredients of carfilzomib:

Fall and drugs with ingredients of carfilzomib (186 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kyprolis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fall:

Fall (3,288 drugs)

Browse all the conditions that are associated with Fall:

Fall (3,757 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carfilzomib (the active ingredients of Kyprolis) and Kyprolis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.